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Abstract: A class of drugs called coxibs (COX-2 inhibitors) were created to help relieve pain and
inflammation of osteoarthritis and rheumatoid arthritis with the lowest amount of side effects possible.
The presented paper describes a new developed, optimized and validated thin layer chromatographic
(TLC)-densitometric procedure for the simultaneous assay of five coxibs: celecoxib, etoricoxib,
firecoxib, rofecoxib and cimicoxib. Chromatographic separation was conducted on HPTLC F254
silica gel chromatographic plates as a stationary phase using chloroform–acetone–toluene (12:5:2,
v/v/v) as a mobile phase. Densitometric detection was carried out at two wavelengths of 254 and
290 nm. The method was tested according to ICH guidelines for linearity, recovery and specificity.
The presented method was linear in a wide range of concentrations for all analyzed compounds,
with correlation coefficients greater than 0.99. The method is specific, precise (%RSD < 1) and accurate
(more than 95%, %RSD < 2). Low-cost, simple and rapid, it can be used in laboratories for drug
monitoring and quality control.
Keywords: coxibs; TLC-densitometry; validation of the method; human and veterinary drugs
1. Introduction
The search for new non-steroidal anti-inflammatory drugs (NSAIDs), since the synthesis of salicylic
acid, has been carried out simultaneously in two main directions, obtaining compounds with higher
anti-inflammatory effects, and compounds with weaker side effects. Over time, the availability of
an increasing number of new, strong representatives of this group of drugs increased, but the
problem of their toxic effects, especially on the gastrointestinal tract and kidneys, remained
unresolved. A breakthrough in the search led to the discovery of several isoforms of cyclooxygenase
(COX) [1]. The goal of the creation of NSAIDs was to stop prostaglandin production as the main
cause of inflammation, pain and fever. The mechanism of their action is the inhibition of the
cyclooxygenase enzyme responsible for the transformation of arachidonic acid, and the formation of
signal molecules—prostaglandins. However, as it turned out in later studies, there are two isoforms
of this enzyme, COX-1 (along with the COX-3 subtype) and COX-2, and prostaglandins performs
many varied and physiologically important functions in the body. The elementary description of the
differences between the two isoforms is that COX-1 occurs mainly physiologically in the human body,
while COX-2 is a constitutive isoform arising primarily in places of tissue damage and dysfunction.
COX-1 occurs naturally in many important organs, and regulates their work, e.g., regulation of renal
blood flow, formation and functioning of platelets and the presence of blood vessels in the endothelium.
The COX-2 isoform is mainly recognized in pathological conditions, but it has been proven that it can
also be constitutively present in small amounts in organs, e.g., kidneys, where both types complement
each other [2–5]. The distribution of both enzyme isoforms is subject to fairly high species variability
in mammals and even individual variation. The most known and commonly used NSAIDs inhibit
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both enzyme types (e.g., ibuprofen, diclofenac). In this case, serious side effects associated with COX1
inhibition (gastric mucosal damage, kidney damage) may occur. In order to minimize the adverse
effects, more selective blocking of the COX-2 isoform than COX-1 (e.g., meloxicam) and the completely
selective blocking of COX-2 (group of “coxibes”) was sought.
The aforementioned group of selective COX-2 inhibitors has a much weaker gastrotoxic effect
compared to other NSAIDs, and their therapeutic effectiveness is compared to the action of reference
drugs, i.e., ibuprofen or naproxen [6,7]. Coxibs are used primarily to treat inflammation and pain in
osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. They are also commonly used for the
short-term treatment of acute pain conditions [8]. Conducted research suggests that they may affect
cartilage metabolism by inhibiting cartilage matrix formation (e.g., naproxen or indomethacin), or by
stimulating it (e.g., aceclofenac) or without affecting its synthesis (e.g., piroxicam) [9]. Unfortunately,
some drugs, also from the group of COX-2 inhibitors, may increase the risk of cardiovascular incidents
(e.g., rofecoxib) [10].
Celecoxib was the first coxib introduced to human medicine. The development of this group of
drugs was stopped when increased cardiotoxicity was found in randomized clinical trials. This led
to the withdrawal from the market, among others—rofecoxib and valdecoxib. The use of coxibs
in humans has since been significantly reduced [11–14]. At the same time, many representatives of
NSAIDs used in human pharmacotherapy have found use in veterinary medicine. Unfortunately,
a large group of these drugs cannot be used in veterinary treatment because of their high toxicity to
animals. Deracoxib, firocoxib, mavacoxib, robenacoxib, and cimicoxib have been registered since the
2000s. Osteoarthritis is the main indication for the use of this group of drugs in veterinary medicine.
In addition, they are used in postoperative pain and bone fractures [15–18]. Firocoxib and deracoxib are
active ingredients in drugs indicated for use in dogs [19]. In one field trial, firocoxib showed improved
efficacy in some measurement over the less COX-1 sparing NSAID carprofen [20]. In the other field
trial, dogs treated with firocoxib showed significantly greater improvement in osteoarthritis-related
pain and lameness, and a significantly reduced incidence of diarrhea relative to dogs treated with
etodolac [21]. Currently, there are more and more studies exploring the possibility of using selective
COX2 inhibitors in oncological treatment in both animals and humans [22–25].
There are a number of spectrophotometric and liquid chromatographic (with various detectors)
methods reported in the literature for the assays of the selected five representatives of selective
COX-2 inhibitors (celecoxib, etoricoxib, cimicoxib, firocoxib and robenacoxib) in various materials,
biological samples and pharmaceuticals [26–35]. There were also publications in which these drugs
were determined in animal and environmental samples [16,36–38]. However, no method for the
simultaneous determination of those active substances in dosage forms has been studied so far. On this
basis, it became apparent to develop and validate a new, simple, sensitive and accurate methodology
for the simultaneous estimation of these drugs (Figure 1) in pharmaceutical preparations (human and
veterinary), using the thin layer chromatographic (TLC) technique. TLC with densitometric detection
is a rapid and non-complicated analytical technique for the separation, identification and quantification
of medicinal substances. It is simple and low cost, and the minimal need for cleaning of the sample
allows for the conduction of various types of analyses in different areas of science.
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2.1. Materials and Methods
2.1.1. Chemicals and Apparatus
Methanol, chloroform, acetone, toluene, ethyl acetate, ammonia, glacial acetic acid, and other
organic solvents were purchased from Merck (Darmstadt, Germany). All chemicals were analytical
grade. HCl, NaOH and H2O2 solutions were purchased from POCh, Gliwice, Poland. Buffer solutions
(pH 2—citrate buffer, pH 7—phosphate buffer, pH 8—borate buffer) were purchased from Witko
(Łódź, Poland). Densitometer TLC Scanner 3 with Cat4 software (CAMAG, Muttenz, Switzerland),
Linomat 4 (CAMAG, Switzerland), analytical balance XA 52/Y (Radwag, Poland) were used.
Chromatographic plates TLC Silica gel 60F254 (no 1.05554), HPTLC Silica gel 60F254 (no 1.05548),
TLC Kieselgel 60WF254s (no 16484), TLC Cellulose F (no 1.05574) were all purchased from Merck
(Darmstadt, Germany).
2.1.2. Standard Substances and Solutions
Celecoxib (no PHR1683), etoricoxib (no 32097) and firocoxib (no 32236) were purchased from
Sigma-Aldrich (L ramie, WY, USA). Due to the lack of available standard substances, pure compounds
of cimicoxib and robenacoxib were obtained from their preparations. Extraction from their preparations
was carried out using diethyl ether (POCh, Gliwice, Poland). The weight of the preparation was
shaken successively with three portions of ether, the filtrate was collected, and then the solvent was
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evaporated until a dry residue was obtained. The obtained compounds were subjected to infrared
spectrophotometric analysis. Methanol solutions (about 1% (w/v)) were also made, and subjected to
TLC analysis under the conditions described below (analysis of RF values and absorption spectra).
No additional peaks were received on the obtained chromatograms.
The identities of the obtained substances were confirmed by infrared spectrophotometry. Finally,
pure substances were obtained, and they were used in later studies.
Pharmaceutical preparations: Celebrex (Pfizer Europe, UK) containing 200 mg of celecoxib, Arcoxia
(MSD, Warszawa, Poland) containing 120 mg of etoricoxib, Previcox (Boehringer Ingelheim Vetmedica
GmbH, Ingelheim am Rhein, Germany) containing 227 mg of firocoxib, Cimalgex (Vétoquinol SA,
France) containing 80 mg of cimicoxib and Onsior (Elanco GmbH, Cuxhaven, Germany) containing
40 mg of robenacoxib, were used. All preparations were purchased from the local pharmacy or
veterinary office. Preparations had an expiry of no less than one year at the time of study.
Standard solutions were prepared individually by dissolving an accurately-weighed 10.0 mg of
each standard in 10.0 mL of methanol, and stored in the dark at 4 ◦C for up to three days.
2.1.3. Samples Solutions
Samples solutions were prepared by powdering five tablets or capsules. Next, each tablet powder
was weighed to an accuracy of 0.1 mg, and a quantity of equivalent to 10.0 m. Each drug was weighed
and transferred separately into a 10.0 mL volumetric flask containing approximately 5.0 mL methanol.
Each samples were shaken on a laboratory shaker (Lab Dancer V Vario, Imlab) for 5 min and the
volume was made up to the mark with methanol. Prepared solutions were filtered through filter paper
and all filtrates were used for the analysis.
2.1.4. Chromatographic Conditions
Chromatography was performed on 10 × 10 cm aluminum sheets precoated with 200 µm layers
of silica gel 60 F254 (E. Merck, Darmstadt, Germany). Samples were applied to the plates as bands
that were 5 mm wide and 10 mm apart by means of a Linomat V (CAMAG, Switzerland) sample
applicator equipped with a 100 L syringe (Hamilton, Switzerland). The first application was 10 mm
from the bottom and 10 mm from the left edge of the plate. The application rate was 600 nL/s. Samples
were developed in different mobile phases and various separation lengths. Plates were taken into
a chromatographic chamber (18 × 16 × 8 cm; Sigma-Aldrich, Laramie, WY, USA) previously saturated
with mobile phase vapor for 20 min in room temperature. Good separation and well-developed
peaks were obtained with mobile phase containing with chloroform–acetone–toluene (12:5:2, v/v/v).
The development distance was 10 cm during 20 min. After development, plates were dried in room
temperature for about 20 min. Densitometric scanning was performed using a CAMAG TLC Scanner 3
with winCats 4 software (Muttenz, Switzerland). The source of radiation was the deuterium lamp
emitting a continuous UV spectrum between 200 to 400 nm. Scanning speed was 20 mm/s and slit
dimensions were 4.00 × 0.45 mm. Plates were scanned over the range of 200–400 nm and the spectra
were overlaid. Based on the obtained spectra, analytical wavelengths were chosen for detection all
analyzed coxibs.
2.2. Validation of the Method
The validation procedure of the proposed method was performed with respect to specificity,
linearity and range, limits of detection and quantification, precision, and robustness, according to ICH
guidelines [39].
2.2.1. Selectivity
The separation factor α, calculated by equation α = [(1/RF1) − 1]/[(1/RF2) − 1] (where: RF1 and
RF2—the retardation factor for 1 and 2 substance), is a chromatographic parameter that determines the
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selectivity of separation of two adjacent compounds in a given chromatographic system. Its value
should be higher than 1.0.
To ensure the accuracy of quantitative analysis, it is also important to determine the value of the
resolution factor R, calculated by the equation R = [2 (Z2 − Z1)]/(W1 + W2) (where: Z1 and Z2—the
separation distance of two adjacent peaks 1 and 2, W1 and W2—the width of two adjacent peaks 1 and
2). It determines the possibility of resolution analysis for two adjacent peaks, and it should be no less
than 1.
2.2.2. Range and Linearity
The range and linearity of the method were verified by analyzing of a set of ten calibration
mixtures in the concentration ranges of 0.10–10 mg/mL for celecoxib, 0.02–10 mg/mL for etoricoxib,
0.40–10 mg/mL for firocoxib, 0.05–7 mg/mL for cimicoxib and 0.05–10 mg/mL for robenacoxib.
To develop the calibration curves, peak area and drug concentration data were treated by linear
least-square regression analysis.
The dependence of the substance concentration on the densitogram peak area is rectilinear
only within a certain range. Regression parameters were determined, such as slope (a), intercept
(b), standard deviation of a slope (Sa), standard deviation of an intercept (Sb), estimation error (Se),
correlation coefficient (r). Based on the obtained results for each regression equation, the analysis of
residuals was also completed.
2.2.3. Limit of Detection (LOD) and Limit of Quantification (LOQ)
The LOD is the smallest amount (concentration) of the tested substance in the sample that
can be detected but not necessarily determined with appropriate accuracy. The smallest amount
of substance that can be determined with a certain precision and accuracy is named the LOQ.
Both parameters are very important and needed when using the method for determining a drug
substance in pharmaceutical preparations. The LOD and LOQ were calculated based on obtained
calibration curve values, respectively as: LOD = (3.3 · Sb)/a and LOQ = (10 · Sb)/a, where: Sb—the
standard deviation of the intercept, a—the slope of the calibration curve.
2.2.4. Precision
Precision is defined as checking the extent in which the results of analyses carried out on the same
sample will be compatible with each other. The precision of analytical methods was assessed regarding
repeatability (intra-day precision) and intermediate precision (inter-day precision). The percentage of
relative standard deviation (%RSD) of the obtained peak areas was taken as the measure of precision.
To study intra-day precision, six standard solutions containing respectively 600 ng/band of celecoxib,
400 ng/band of etoricoxib, 900 ng/band of firocoxib, 800 ng/band of cimicoxib and 1000 ng/band of
robenacoxib were prepared, applied to chromatographic plates and developed under the conditions
described in Section 2.1.4. Each replicate was created under the same operating conditions and over
a short interval time. Inter-day precision was created for the same samples by performing the analysis
after a week.
2.2.5. Accuracy
To evaluate the accuracy of the method, recovery studies were carried out by addition of standard
substance solution to pre-analyzed sample solutions at three different concentration levels: 80%, 100%,
and 120%. The recovery percentages (R [%]) were calculated by formula: R [%] = [(A1 − A2)/A2]
× 100%, where: A1—peak area for sample after adding analyte, A2—peak area for sample before
adding analyte.
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2.2.6. Robustness
The robustness measures the ability of an analytical method to remain intact after small, deliberate
changes in method parameters. It provides guidance on the reliability of the analytical method during
normal use. The robustness of the proposed method was evaluated by the reliability of the analysis with
respect variations in the experimental conditions, such as the sorbent type (TLC 60F254, HPTLC 60F254,
TLC 60WF254s, TLC Cellulose F), the chamber type (12 × 11 × 8 cm, 27 × 27 × 7 cm), the distance of
development (±0.5 cm), saturation time of the chamber (±5 min), the volume of individual components
in used mobile phase (±0.1 mL).
2.3. Stability-Indicating Study
The Food and Drug Administration (FDA) and International Conference on Harmonization (ICH)
state the requirement of stability testing data to understand how the quality of a drug substance
and drug product changes with time under the influence of various environmental factors [19,39].
Based on the guidelines, the following conditions were investigated: hydrolysis at acid (0.5 M HCl),
base (0.5 M NaOH) and buffer solutions (pH 2, 7, 8), thermal degradation (30 ◦C, 80 ◦C), photolysis,
and oxidation (10% H2O2, v/v). Solutions of individual drugs were prepared by dissolving the weight
in an appropriate solution of acid, base, H2O2, buffer or methanol. Aliquots of 1 mL of each drug
solution were transferred to minivials and heated at 30 or 80 ◦C for 1 and 3 h. Sequentially harvested
portions of the test solutions were diluted with methanol to the proper volume and applied onto
the HPTLC plates and analyzed as described above. A sample powder of each drug was exposed
to sunlight for seven days. Next, the substances were dissolved in methanol, and applied onto the
chromatographic plates. At the same time, similar determinations were made for neutral samples
(methanol solutions).
2.4. Analysis of Pharmaceutical Formulations
Ten tablets, or the content of ten capsules of each commercial product, were separately mixed
and weighed. Individual amounts of each product equivalent to 5.0 mg of each drug substance was
dissolved in 50.0 mL of methanol. After shaking for 20 min, all solutions were filtered using a 0.2 m
Whatman filter paper and used in further research. Standard and sample solutions (6 µL) were applied
to the plate and analysis was performed as described above.
3. Results and Discussion
The quality of pharmaceutical products is very important to maintain the overall healthcare
of millions of patients. This study presents a new validated isocratic method based on the TLC
separation for simultaneous resolution and quantification of selected COX-2 inhibitors, e.g., celecoxib,
etoricoxib, firecoxib, robenacoxib and cimicoxib in human and animal pharmaceuticals. The presented
procedure was developed taking into account the therapeutic and overdose concentration range.
It was validated and verified for the determination of mentioned drugs in raw materials and
pharmaceutical formulations.
Several problems are associated with the simultaneous determination of investigated compounds.
The first is the choice of separation conditions to ensure efficient drug extraction with minimal
interference from the matrix (especially from veterinary preparations). The other is choosing the
right chromatographic conditions to achieve the separation of all compounds simultaneously.
Next, the method must be sensitive enough to determine the concentrations of tested drugs in
their therapeutic range.
To optimize the conditions of the TLC-densitometric method, a number of parameters were
varied, such as the type of stationary phase, the mobile phase composition and the developing
distance. Based on the literature data and eluotropic series, various ratios of different organic solvents
(e.g., methanol, chloroform, acetone, toluene, ethyl acetate, ammonia, glacial acetic acid) were tested.
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For the simultaneous determination of five coxibs, individual drug solutions were spotted onto the
different chromatographic plates and developed at various distances using different mobile phases.
The variation in the stationary and mobile phases led to considerable changes in the chromatographic
parameters, like a peak symmetry and retardation factor.
As a result of these experiments, optimal conditions were determined for the analysis of selected
coxibs side by side, conducting assays on HPTLC 60F254 chromatographic plates as the stationary
phase, and a mixture consisting of chloroform–acetone–toluene in a volume ratio of 12:5:2 as the
mobile phase. The selected analysis conditions allowed for the simultaneous determination of all five
drug samples.
The obtained chromatograms were subjected to densitometric detection. In the described
conditions, the peak shape and resolution were found to be good. The determined values of retardation
factors (RF) for individual substances are shown in Table 1. The representative densitogram obtained
from a mixed standard solution of analyzed substances is shown in Figure 2.
Table 1. Retardation (RF), resolution (α) and separation (R) factors.
Substance RF α R
cimicoxib 0.25 - -
robenacoxib 0.34 1.3 1.6
etoricoxib 0.45 1.3 2.8
celecoxib 0.71 3.2 5.9
firocoxib 0.83 1.4 1.4
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In addition, the absorption spectra of individual compounds were recorded in the wavelength
range from 200 to 400 nm, and compared. All analyzed coxibs show maxima of absorption in the range
from 230 to 300 nm (Figure 3); celecoxib and cimicoxib showed considerable absorbance at 254 nm,
but etoricoxib, firocoxib and robenacoxib showed a maximum of absorbance at 290 nm. Based on
these observations, two wavelengths, 254 and 290 nm, were chosen for the quantification of individual
coxibs. The choice of using common wavelengths was considered satisfactory to allow the detection
and analysis of all tested drugs with appropriate sensitivity. The identities of each substance on the
densitograms were confirmed by comparing the RF values and the absorption spectra of separated
peaks with those obtained for standards.
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The separation factor α and resolution factor R, calculated for every two adjacent peaks are
presented in Table 1. All obtained values are higher than 1; it can be stated that the developed
conditions allow for the correct separation and analysis of selected coxibs.
The concentration of a set of solutions used for the range analysis were the same as in Section 2.2.2.
Peak area (P) and drug concentration (C) data were treated by linear regression analysis. The plots
P vs. C of each coxib were found to be linear over a range of 0.10–5 mg/mL for celecoxib, 0.02–5 mg/mL
for etoricoxib, 0.40–6 mg/mL for firocoxib, 0.05–7 mg/mL for cimicoxib and 0.10–10 mg/mL for
robenacoxib. Linear regression equations representing the calibration curves and the regression
parameters, such as slope, intercept, standard deviation of the slope and intercept, an estimation
error and the correlation coefficients are shown in Table 2. The results showed excellent prediction
for the set-in high values of correlation coefficients, ranging between 0.98 and 0.99 for all analytes.
This confirms the high predictive ability of the developed method.
Table 2. Regression equations and validation parameters obtained for analyzed compounds.
Parameter Celecoxib Etoricoxib Firocoxib Cimicoxib Robenacoxib
λ = 254 (nm)
Linearity (mg/mL) 0.30–5.00 0.10–5.00 0.60–6.00 0.10–7.00 0.20–10.00
a 3069.28 3733.77 1598.63 2725.37 1484.92
b 1103.12 1169.34 223.43 1205.32 601.22
Sa 225.33 242.61 55.00 165.63 39.35
Sb 583.05 627.13 184.23 603.66 218.90
Se 871.41 960.96 240.71 1022.26 319.49
r 0.9894 0.9916 0.9952 0.9927 0.9986
r(res) 0.47 × 10−6 0.20 × 10−6 0.13 × 10−6 0.51 × 10−7 0.11 × 10−6
CD 0.9772 0.9437 0.4886 0.5102 0.2388
LOD (ng/band) 93.69 84.93 49.71 32.78 71.00
LOQ (ng/band) 283.91 257.37 150.63 99.34 215.16
λ = 290 (nm)
Linearity (mg/mL) 0.10–5.00 0.02–3.00 0.40–4.00 0.05–3.00 0.10–10.00
a 1097.24 5483.18 3003.35 4281.88 1498.74
b 758.60 644.69 −118.54 −369.07 488.84
Sa 74.78 189.1 164.93 204.52 41.24
Sb 192.63 352.28 381.60 382.10 224.85
Se 301.07 492.13 492.39 528.69 361.14
r 0.9908 0.9976 0.9940 0.9954 0.9985
r (res) 0.20 × 10−6 0.40 × 10−6 1.10 × 10−1 0.40 × 10−6 0.38 × 10−7
CD 0.8276 0.4462 0.6400 0.4337 0.2176
LOD (ng/band) 90.55 29.62 54.10 40.75 79.52
LOQ (ng/band) 274.41 89.75 163.95 123.46 240.96
λ—wavelength [nm]; a—slope; b—intercept; Sa—standard deviation of the slope; Sb—standard deviation of the
intercept; Se—estimation error; r—correlation coefficient; r (res)—correlation coefficient for a plot of residuals;
CD—Cook’s distance (mean).
Detection and quantification limits were calculated following the formula presented in Section 2.2.3.
The calculated LOD and LOQ values are in the range of 29.62 to 93.69 ng/band and from 89.75 to
283.91 ng/band, respectively. The obtained data, presented in Table 2, demonstrated relatively low
values, which indicates that the developed method is sufficiently sensitive to analyzed drugs.
Based on the calculated LOQ values and plotted calibration curves, it was found that the standard
calibration curves are linear in the respective concentration ranges for individual compounds at both
wavelengths (Table 2), with correlation coefficients (r) close to 0.99.
Plotting the residuals helps to identify problems with poor or incorrect curve fitting. If there is
a good fit between the data and the regression model, the residuals should be distributed randomly
about zero. For this purpose, the correctness of obtained correlations was determined for each regression
equation based on residual analysis. Figure 5 displays an example of a scatterplot of residuals for
concentration values.
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Figure 5. An example of the plot of residuals for firocoxib at 254 nm (A) and celecoxib at 290 nm (B).
For the obtained results, we can conclude that the residuals locate around zero and are randomly
scattered without any patterns. The values of correlation coefficients for individual plots of residuals
are presented in Table 2. This random feature confirms that there is no trend in the spread of residuals
with concentration, and the assumption of linearity is correct.
The parameter CD, Cook’s distance, was also determined for each point (Table 2). CD is used in
regression analysis to find influential outliers in a set of prediction variables. It is a way to identify
points that negatively affect a regression model. The obtained values in all cases are convergent and
are in the range from 0.2176 to 0.9772. Based on the received parameters for the examined points,
no significant deviations that could disturb the received regression were found.
The precision of the proposed method was assessed by analyzing peak areas obtained for all
the studied compounds within the same day (for intra-day precision) and after a week (for inter-day
precision). The method passed the tests as determined by %RSD of the area of the peaks of six replicate
injections at 100% test concentration. The low values of %RSD (not higher than 1.22) indicated good
precision of the developed method (Table 3) for all drug substances at both wavelengths.
Table 3. Results of the method precision.
Parameter Celecoxib Etoricoxib Firocoxib Cimicoxib Robenacoxib
λ [nm] 254 290 254 290 254 290 254 290 254 290
Intra-day precision
xm 3005.75 7420.98 4029,27 1649.43 2961.85 5134.45 6479.98 4100.50 5875.85 9630.23
SD 29.01 64.68 37.70 17.26 26.77 16.37 59.68 34.87 46.11 89.18
Sxm 11.85 26.41 15.39 7.05 10.93 6.68 24.37 14.24 18.83 36.41
%RSD 0.97 0.87 0.94 1.05 0.90 0.32 0.92 0.85 0.78 0.93
Inter-day precision
xm 3014.60 7422.07 4027.55 1656.52 2958.05 5130.57 6504.10 4117.62 5870.15 9638.03
SD 21.68 45.67 40.35 20.27 25.52 33.98 47.74 49.05 34.45 78.34
Sxm 8.85 18.64 16.47 8.28 10.42 13.87 19.49 20.02 14.06 31.98
%RSD 0.59 0.81 0.73 1.19 0.86 0.66 1.00 1.22 0.72 0.62
xm—arithmetic mean; SD—standard deviation; Sxm—standard deviation of the mean; RSD—relative standard
deviation [%].
To verify the applicability of the method, the recovery experiment of the selected coxibs in
pharmaceutical preparations was performed. Before drug determination, the celecoxib, etoricoxib and
firocoxib were spiked into their preparations. After shaking, solutions of standard substances and
solutions of proper pharmaceutical preparations—the spiked samples—were spotted onto the HPTLC
plate and determined in conditions, as described in Section 2.2.5.
Satisfactory recovery demonstrated that the developed method is reliable and sensitive for
simultaneous determination of analyzed coxibs. The percent recovery results were satisfactory, ranging
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from 93.65% to 106.20% with %RSD lower than 2% (Table 4). The obtained results also confirmed that
the excipients in commercial formulations do not interfere with the studied compounds.
Table 4. Results of the accuracy.
Substance λ (nm)
Level of Concentration
80% 100% 120%
% Recovery %RSD % Recovery %RSD % Recovery %RSD
celecoxib
254 99.16 1.52 99.23 0.99 95.08 1.58
290 98.08 1.86 98.91 0.88 93.65 1.23
etoricoxib
254 97.91 2.06 100.06 1.32 95.17 1.75
290 98.08 1.70 99.29 1.00 98.89 1.76
firecoxib
254 96.07 1.37 98.16 0.99 105.95 1.03
290 99.93 0.95 99.95 0.90 101.25 0.48
cimicoxib
254 98.68 0.85 99.98 0.49 100.33 0.75
290 98.20 0.90 98.30 1.01 101.30 1.10
robenacoxib
254 100.85 1.31 100.67 1.21 101.64 1.20
290 99.19 0.73 99.71 0.78 98.23 0.92
The robustness of the TLC-densitometric procedure was evaluated by small changes in experiment
conditions, such as sorbent type, chamber type, distance of development, saturation time of the
chamber, volumes of the mobile phase components. On the basis of obtained results (analysis of RF
values and absorption spectra), it was observed that there were no marked significant changes in
chromatographic behavior for all analyzed coxibs, indicating that the method is robust.
Due to the fact that all analyzed compounds show relatively high values of absorbance at selected
wavelengths, validation of the developed procedure was executed at two wavelengths, 254 and 290 nm.
Obtained results are satisfactory, and indicate the possibility of carrying out determinations of tested
coxibs at both wavelengths with appropriate precision in a various concentration ranges.
Summarizing the results, it can be said that the validation process of an analytical method including
the TLC-densitometric method is a very powerful tool, necessary in the quantitative determination of
analyzed coxibs in their pharmaceutical formulations, like tablets and capsules. The validation report
indicates that the developed method fulfills the criteria of an analytical method designated for quantity
control of pharmaceuticals in terms of specificity, linearity, limits of detection and quantification,
precision, accuracy and robustness.
The chemical stability of pharmaceutical substances is a very important issue because it affects
the safety and efficacy of the pharmaceutical product. Forced degradation study of a substance and
a product under accelerated conditions shows the chemical behavior of the molecule, which in turn
helps in the formulation and packaging. Stress tests are conducted under extreme conditions to
demonstrate the specificity of the developed method of measuring changes in drug concentration
when little information is available on the potential degradation product, and to confirm the stability
of the compound during the given analytical procedure [40]. In studied conditions (hydrolysis at acid,
base and buffer solutions, thermal degradation, photolysis and oxidation) no additional peaks for
degradation products on chromatograms were obtained. The peak area from individual substances did
not decrease, which proves the stability of the tested compounds in the described conditions, and the
selectivity of the developed method for the tested coxibs.
In the next step, the developed method was successfully applied for the determination of individual
drug contents in their pharmaceutical preparations. The content of all substances in the examined
products were determined on the basis of previously described conditions, in ranges of linearity and at
the selected analytical wavelength (254 nm for celecoxib and cimicoxib, 290 nm for etoricoxib, firocoxib
and robenacoxib). The obtained results of TLC-densitometric analysis of five coxibs with statistical
analysis are demonstrated in Table 5.
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Table 5. Results from assay of celecoxib, etoricoxib, firocoxib, cimicoxib and robenacoxib in their
pharmaceutical formulations.
Preparation
Declared Content Determined Content
Statistical Analysis
(mg/Tablet or Capsule) (mg/Tablet or Capsule)
Celebrex 200 mg of celecoxib
201.22 201.07 xm = 200.12
199.97 200.08 SD = 0.88
198.93 200.42 Sxm = 0.33
199.14 RSD = 0.44
Arcoxia 120 mg of etoricoxib
120.33 121.11 xm = 120.45
119.85 120.56 SD = 0.48
121.02 110.98 Sxm = 0.18
120.27 RSD = 0.40
Previcox 227 mg of firocoxib
226.72 226.44 xm = 227.06
226.90 227.15 SD = 0.60
228.08 227.61 Sxm = 0.23
226.53 RSD = 0.26
Cimalgex 80 mg of cimicoxib
79.23 80.14 xm = 79.49
79.37 78.98 SD = 0.53
79.20 80.36 Sxm = 0.20
79.17 RSD = 0.67
Onsior 40 mg of robenacoxib
40.24 39.77 xm = 39.77
39.50 39.41 SD = 0.35
39.96 39.39 Sxm = 0.13
40.13 RSD = 0.88
xm—arithmetic mean; SD—standard deviation; Sxm—standard deviation of the mean; RSD—relative standard
deviation [%].
The obtained content of each active substance in the examined drugs shows a very good agreement
to the amount declared by manufacturers. This indicated acceptably-good accuracy and precision in
the analysis of coxibs in tablets and capsules form. The obtained results confirm the suitability of the
developed method.
The obtained parameters are similar to the methods created by other researchers in the field of
coxib analysis. In Rajmane et al.’s work, where the authors determined etoricoxib in combination
with thiocolhicoside by HPTLC, LOQ 33.314 ng/band and recovery near 100% was obtained [32].
Rao et al. analyzed inhibitors COX-2 (celecoxib, rofecoxib, valdecoxib, nimesulide and nabumetone)
in pharmaceutical preparations and in human plasma using RP-HPLC. The obtained percentage
recoveries were between 97.55%–100.14%, and LOD in the range from 127 to 1040 µg/L [41]. Another
method of analyzing COX-2 inhibitors in human plasma by HPLC was developed for celecoxib and
rofecoxib, with the linearity range between 20–2000 µg/L and the LOQ, 20 µg/L [42].
The presented newly developed method also offers many advantages, such as a low cost, the lack
of need for any pre-treatment, and the analysis of several samples for all analyzed compounds
simultaneously during one analysis (on one plate). It can be used in wide concentration ranges
of celecoxib, etoricoxib, firocoxib, cimicoxib and robenacoxib with high stability, sensitivity and
reproducibility. The method did not show any notable deviations in results from acceptable limits.
Despite the fact that the analyzed coxibs are not used simultaneously, the presented method allows
for quick and easy checking, taking into account which substance is used and in what quantity in the
analyzed sample.
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4. Conclusions
Under the described optimized conditions, the complete separation of five coxibs, i.e., celecoxib,
etoricoxib, firocoxib, cimicoxib and robenacoxib, was observed. The performed analysis indicated
that none of the excipients presented in drug formulations interfered with the proposed assay
method. This offers possibilities for the simultaneous assay of five similar substances in one analytical
procedure condition with good separation and resolution of the chromatogram peaks. The developed
TLC-densitometric method is fast, reliable and cost-effective and can be used for the analysis of the
studied drugs in commercial pharmaceutical products with good selectivity, precision and accuracy.
The use of TLC has advantages over, e.g., the HPLC method, such as: a lack of need to thoroughly
clean samples, the ability to perform analyses of several samples at the same time, the subsequent
storage of plates, as well as a greater number of detection methods. The LOQ, small sample volume
and short chromatography time per analysis—without the need for special sample preparation and
costly solvents—makes it advantageous to be adapted to routine assay requirements in quality control
laboratories, and stability studies.
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